SCHEMBL477635

SCHEMBL477635

CC(C)(C)c1ccc(C(O)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
TYR P14679 1/20 0.44
EPHX1 P07099 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RIPK1 Q13546 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
BCHE P06276 1/20 0.41
AOC3 Q16853 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28973554 1.00 LMNA (0.44) LMNATYREPHX1SMN1; SMN2RIPK1
SCHEMBL477443 1.00 LMNA (0.44) LMNATYREPHX1SMN1; SMN2RIPK1
SCHEMBL26326672 0.94 CA12 (0.50) EPHX1CA12CA1CA2CA9
SCHEMBL10708786 0.91 LMNA (0.52) LMNATYRTDP1
SCHEMBL3586191 0.91 LMNA (0.52) LMNATYRTDP1
SCHEMBL11642416 0.90 CA12 (0.46) CA12CA1CA2CA9CA14
SCHEMBL7110307 0.83 CYP3A4 (0.45) LMNASMN1; SMN2RIPK1L3MBTL1BCHE
SCHEMBL16487204 0.82 SLC6A2 (0.44) LMNATYREPHX1L3MBTL1MAPT
SCHEMBL18623182 0.81 CA1 (0.51) LMNATYREPHX1MAPTTDP1
SCHEMBL8671295 0.81 SMN1; SMN2 (0.58) LMNASMN1; SMN2L3MBTL1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116903476-A Large-steric-hindrance polybasic aniline/phenol and preparation method thereof 青岛科技大学 2023-10-20 CN disclosed
CN-114014869-B Chiral 2,2' -bipyridine ligand and preparation method and application thereof 西安交通大学 2023-03-24 CN disclosed
US-8563786-B2 Method for producing optically active alcohol MITSUI CHEMICALS, INC. (JP) 2013-10-22 US disclosed
US-8329855-B2 Thienocoronene-imide semiconducting compounds and polymers POLYERA CORPORATION (US) 2012-12-11 US disclosed
US-20120264900-A1 THIENOCORONENE-IMIDE SEMICONDUCTING COMPOUNDS AND POLYMERS USINVEST LLC 2012-10-18 US disclosed
US-20120088938-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2012-04-12 US disclosed
EP-2412694-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL Mitsui Chemicals, Inc. (JP) 2012-02-01 EP disclosed
US-20110226338-A1 PYRROLO[3,2-B]PYRROLE SEMICONDUCTING COMPOUNDS AND DEVICES INCORPORATING SAME RAYNERGY TEK INC. (TW) 2011-09-22 US disclosed
US-20110213117-A1 Organic Semiconducting Polymers POLYERA CORPORATION (US) 2011-09-01 US disclosed
US-20110120558-A1 SEMICONDUCTOR MATERIALS PREPARED FROM RYLENE-(PI-ACCEPTOR)COPOLYMERS BASF SE 2011-05-26 US disclosed
US-20110079773-A1 Selectively Functionalized Rylene Imides and Diimides NORTHWESTERN UNIVERSITY 2011-04-07 US disclosed
EP-1562901-B1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES SCHERING CORP (US) 2010-06-02 EP disclosed
US-7476681-B2 anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia SCHERING CORPORATION (US) 2009-01-13 US disclosed
US-7476681-B2 anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia SCHERING CORPORATION (US) 2009-01-13 US disclosed
US-6166072-A Amino acid derivatives ALLELIX NEUROSCIENCE, INC. (CA) 2000-12-26 US disclosed
WO-1999034790-A1 GLYCINE TRANSPORT INHIBITORS ALLELIX NEUROSCIENCE, INC. (US) 1999-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110079773-A1 Selectively Functionalized Rylene Imides and Diimides RAE1, RICTOR, RET LMNA 4484/4885TYR 216/4885EPHX1 3814/4885
US-20120264900-A1 THIENOCORONENE-IMIDE SEMICONDUCTING COMPOUNDS AND POLYMERS TST, TPR, SLC19A2 LMNA 4411/4885TYR 208/4885EPHX1 2093/4885
US-20120088938-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL ADH1A, ADH1C, FHIT LMNA 1422/4885TYR 144/4885EPHX1 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.